Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regenxbio (RGNX) Net Margin (2016 - 2025)

Regenxbio has reported Net Margin over the past 12 years, most recently at 221.4% for Q4 2025.

  • Quarterly results put Net Margin at 221.4% for Q4 2025, up 2027.0% from a year ago — trailing twelve months through Dec 2025 was 113.8% (up 15895.0% YoY), and the annual figure for FY2025 was 113.8%, up 15874.0%.
  • Net Margin for Q4 2025 was 221.4% at Regenxbio, down from 208.39% in the prior quarter.
  • Over the last five years, Net Margin for RGNX hit a ceiling of 703.16% in Q4 2022 and a floor of 405.63% in Q1 2024.
  • Median Net Margin over the past 5 years was 244.04% (2024), compared with a mean of 193.59%.
  • Biggest five-year swings in Net Margin: soared 62941bps in 2022 and later plummeted -98664bps in 2023.
  • Regenxbio's Net Margin stood at 73.75% in 2021, then skyrocketed by 853bps to 703.16% in 2022, then crashed by -140bps to 283.48% in 2023, then grew by 15bps to 241.68% in 2024, then grew by 8bps to 221.4% in 2025.
  • The last three reported values for Net Margin were 221.4% (Q4 2025), 208.39% (Q3 2025), and 331.91% (Q2 2025) per Business Quant data.